I achieved the rank of LTC during my training and attending years at Walter Reed Army Medical Center in Washington DC. I spent one year in the Republic of Korea and worked and brought a guinea pig cell line from the NCI to Walter Reed which was associated with CML and blast crisis. I had several publications early on in my career, one of which was in the Inaugural Journal of Clinical Oncology describing late relapse of testicular cancer. I made my way to Chicago to the Chicago College of Osteopathic Medicine and then the Chicago Medical School where I continued my laboratory work and publications. I returned to Detroit to work at Henry Ford Hospital working in malignant hematology. Teaching, patient care and publications followed while writing a book chapter on the Acute Leukemias Symposium which i chaired. I also presented important data on alfa-interferon in CML along with marrow finding with MRI in CML. I have always been involved with cooperative groups and was Principal Investigator for two studies. I joined Ascension Providence where I was the fellowship Program Director for 28 years training while mentoring nearly 100 fellows. Many of these fellows are located at prestigious academic centers or cancer center directors. Publications, national presentations and book chapters followed. I also assumed the role of Providence Cancer Center Director and founded the CAR-T Cellular Program from its inception. I serve on the Scientific Advisory Board (2009-present) for the Connect Registry which is comprised of over 3000 newly diagnosed multiple myeloma patients. There have been over 75 abstracts and manuscripts from this registry. I left Providence and now am at the University of Michigan Hematology and Oncology Section assigned to clinical responsibilities and research in multiple myeloma. Currently I have over 128 manuscript publications

I have focused my research toward hematology (plasma-free hemoglobin), purification of kallikrein at the NIH, then in vivo cell like of a Guinea pig CML blast crisis model utilizing agents to prevent blast crisis. I created a lab both at Walter Reed and Chicago College of Osteopathic Medicine with grant money. I have always been involved with cooperative group (CALGC, ECOG and SWOG) research as a principal investigator. I did phase II trials on MDS with WR-2721 (amifostine) in MDS. I have arranged for national conferences in lymphomas and acute leukemias. However, the bulk of my work has been in multiple myeloma from case reports to molecular studies, collaborative epidemiology in African American women and the role of obesity. I am one of ten members on the BMS Scientific Advisory Board on 3500 newly diagnosed multiple myeloma patients. We have published over 75 abstracts and manuscripts and presented nationally and internationally. Several journals have asked for me to review multiple myeloma manuscripts I have also co-authored a manuscript on how to set up a successful registry. Finally, I established, from its inception, the CAR-T Program at Ascension Providence for in relapsed or refractory disease. The Program currently is treating patients with CAR-T in non-Hodgkins's lymphoma as the standard of care. I have authored more than 130 abstracts and manuscripts and received more than three grants